crisaborole (Eucrisa)

From Aaushi
Jump to navigation Jump to search

Introduction

FDA-approval Dec 2016

Indications

* complete or near complete clearance in 1/3 of patients within 1 month[2]

Dosage

Adverse effects

Mechanism of action

Notes

  • manufactured by Palo Alto, California-based Anacor Pharmaceuticals, Inc.

More general terms

References

  1. Brown T FDA Approves Crisaborole (Eucrisa) for Atopic Dermatitis. Medscape. Dec 14, 2016. http://www.medscape.com/viewarticle/873305
    FDA News Release. December 14, 2016 FDA approves Eucrisa for eczema. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533371.htm
  2. 2.0 2.1 Bankhead C MedPageToday. March 7, 2017 American Academy of Dermatology (AAD) Meeting Coverage. Studies Confirm Efficacy of Topical PDE4 Inhibitor - Significant improvement in atopic dermatitis within a week https://www.medpagetoday.com/MeetingCoverage/AAD/63654
    Fowler JF, et al. Crisaborole ointment improves global atopic dermatitis severity: Pooled results from two phase III clinical trials. American Academy of Dermatology (AAD 2017). Abstract 5667.

Database